Immune-mediated syndromes following intravenous bisphosphonate therapy

Keyphrases

• Immune Response 100%
• Aminobisphosphonates 100%
• Zoledronate 100%
• Intravenous Bisphosphonates 100%
• Bisphosphonate Therapy 100%
• Malignancy 66%
• New Onset 66%
• Inflammatory Response 66%
• Crohn's Disease 33%
• Autoimmune 33%
• Peripheral Blood 33%
• Adverse Reactions 33%
• Rheumatoid Arthritis 33%
• Clinical Data 33%
• T Cells 33%
• Intravenous Infusion 33%
• Electronic Chart 33%
• Disease-related 33%
• Retrospective Case Series 33%
• Hemophilia 33%
• Rheumatology 33%
• Cytokine Release 33%
• Specialty Clinic 33%
• Inflammatory Effects 33%
• Polymyalgia Rheumatica 33%
• Zoledronic Acid 33%
• Inflammatory Autoimmune Disorders 33%
• Autoimmune Syndrome 33%
• Aromatase Inhibitor-induced Arthralgia 33%

Medicine and Dentistry

• Bisphosphonate 100%
• Zoledronic Acid 100%
• Serositis 50%
• Infusion 50%
• Cancer 50%
• Adverse Event 25%
• Intravenous Drug Administration 25%
• T Cell 25%
• Autoimmune Disease 25%
• Cytokine Release 25%
• Rheumatoid Arthritis 25%
• Arthralgia 25%
• Crohn's Disease 25%
• Rheumatology 25%
• Haemophilia 25%
• Polymyalgia Rheumatica 25%
• Aromatase Inhibitor 25%

Immunology and Microbiology

• Inflammation Response 100%
• Crohn's Disease 50%
• T Cell 50%
• Inflammatory Arthritis 50%
• Autoimmune Disease 50%
• Cytokine Release 50%
• Rheumatic Polymyalgia 50%